List view / Grid view
An assay is an analytical procedure in laboratory medicine, pharmacology and molecular biology for measuring the activity of a target entity.
In this application note, PerkinElmer demonstrates the ease and utility of using AlphaLISA®, a homogeneous assay format, to screen for small molecular inhibitors of BET bromodomains.
Quickly gain new insights into chemical and biomolecular research data. Featuring guided search and analysis workflows and dynamic data visualisations.
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
2 January 2018 | By Charles River Laboratories
The webinar speakers highlight the collaboration between patient groups, charities, and academia led to the development of inhibitors targeting gliomas.
Better subtyping of diffuse large B-cell lymphomas can enhance diagnosis and guide treatment...
Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.
DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial…
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
In this application note, PerkinElmer demonstrate the utility of an AlphaLISA assay for screening biotherapeutic antibodies and compounds that block binding of human PD-1 and PD-L1.
Blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies...
Charles River Laboratories International, Inc. announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47th annual meeting of the Society for Neuroscience (SfN).
6 October 2017 | By DiscoverX Corporation
In this webinar, we discussed how two qualification studies on KILR CD16 Effector Cells demonstrated accuracy and precision in different assays formats.
In this whitepaper, IntelliCyt Corporation describe how the iQue Screener is used to perform multiplexed screens for antibody binding to either cell surface or to circulating target antigens...
